



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Roman V. Rariy, et al.

Application No: 10/691,465

Filed: October 22, 2003

For: *Stereoisomers of p-Hydroxy-Milnacipran and Methods of Use Thereof*


Art Unit: 1614

Examiner: Not Yet Assigned

Attorney Docket No.: CPX-003.01

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, "Post Office to Addressee" in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on March 25, 2004.


Shirine Darvish

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants and/or their attorney in compliance with the requirements of 37 CFR 1.56. Copies of the documents are also being submitted.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that the cited documents are material or constitute "prior art." If the Examiner applies the listed documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law

Serial No.: 10/691,465
CPX-003.01

regarding the appropriate status of such documents. Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the referenced documents be applied against the claims of the present application.

Under 37 C.F.R. § 1.97 (b)(3), this Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits; therefore, no fee is believed to be due in connection with this submission. However, the Commissioner is authorized to charge any deficiencies or credit any overpayment to/from our **Deposit Account, No. 06-1448, Reference CPX-003.01.**

Respectfully Submitted,



Dana M. Gordon, Ph.D.
Reg. No.: 44,719
Attorney for Applicant

Date: March 25, 2004

Customer No.: 25181

Patent Group
Foley Hoag LLP
SEAPORT WORLD TRADE CENTER WEST
155 Seaport Boulevard
Boston, MA 02210
617-832-1000
617-832-7000 (FAX)

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) CPX-003.01	Application Number 10/691,465
	Applicant Roman V. Rariy, et al.	
	Filing Date October 22, 2003	Group Art Unit 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 5,621,142	04/15/1997	Mochizuki et al.			
	AB 4,478,836	10/23/1984	Mouzin et al.			

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	AC 3-56415	03/12/1991	JP				X

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AD	MORET, C., et al., "Biochemical Profile of Midalcipran (F 2207), 1-Phenyl-1-Diethyl-Aminocarbonyl-2-Aminomethyl-Cyclopropane (Z) Hydrochloride, A Potential Fourth Generation Antidepressant Drug," <u>Neuropharmacology</u> , Vol. 24, No. 12, pgs. 1211-1219, (1985).
AE	GARD, S., et al., "Enhancement of Second-Migrating Enantiomer Peak Symmetry of Basic Drugs by Using Dual-Cyclodextrin System in Capillary Electrophoresis," <u>Electrophoresis</u> 2000, No. 21, pgs. 3028-3034, (2002).
AF	BONNAUD, B., et al., "1-Aryl-2-(Aminomethyl)cyclopropanecarboxylic Acid Derivatives. A New Series of Potential Antidepressants," <u>J. Med. Chem.</u> 1987, No. 30, pgs. 318-325 (1987).
AG	SHUTO, S., et al., "(±)-(Z)-2-(Aminomethyl)-1-phenylcyclopropanecarboxamide Derivatives as a New Prototype of NMDA Receptor Antagonists," <u>U. Med. Chem.</u> 1995, No. 38, pgs. 2964-2968, (1995).
AH	VIAZZO, P., et al. "Microbiological Transformations 34: Enantioselective Hydrolysis of a Key-Lactone Involved in the Synthesis of the Antidepressant Milnacipran®," <u>Tetrahedron Letters</u> , Vol. 37, No. 26, pgs. 4519-4522 (1996).
AI	SHUTO, S., et al., "Synthesis of (+)- and (-)-Milnaciprans and Their Conformationally Restricted Analogs," <u>Tetrahedron Letters</u> , Vol. 37, No. 5, pgs. 641-644 (1996).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

	AJ	SHUTO, S., et al., "Synthesis and Biological Activity of Conformationally Restricted Analogs of Milnacipran: (1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide, an Efficient Noncompetitive N-Methyl-D-aspartic Acid Receptor Antagonist," <u>J. Med. Chem.</u> 1996, No. 39, pgs. 4844-4852, (1996).
	AK	SHUTO, S., et al., "Synthesis and Biological Activity of Conformationally Restricted Analogs of Milnacipran: (1S,2R)-1-Phenyl-2-[(R)-1-amino-2-propynyl]-N,N-diethylcyclopropanecarboxamide Is a Novel Class of NMDA Receptor Channel Blocker," <u>J. Med. Chem.</u> 1998, 41, pgs. 3507 - 3514, (1998).
	AL	DEPREZ, D., et al., "Which Bioequivalence Study for a Racemic Drug? Application to Milnacipran," <u>Eur. J. Drug Metab. Pharmacokinet.</u> 23, pgs. 166-171, (1998).
	AM	PUZZO, C., et al., "Pharmacokinetics of Milnacipran in Liver Impairment," <u>Eur. J. Drug Metab. Pharmacokinet.</u> 23, pgs. 273-279, (1998).
	AN	PUZZO, C., et al., "Pharmacokinetics of Milnacipran in Renal Impairment," <u>Eur. J. Drug Metab. Pharmacokinet.</u> 23, pgs. 280-286, (1998).
	AO	SHUTO, S., et al., "(1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a New Class of NMDA-Receptor Antagonist: Molecular Design by a Novel Conformational Restriction Strategy," <u>Jpn. J. Pharmacol.</u> 85, pgs. 207-213, (2001).
	AP	DOYLE, M., et al., "A New Enantioselective Synthesis of Milnacipran and an Analogue by Catalytic Asymmetric Cyclopropanation," <u>Adv. Synth. Catal.</u> 2003, Vol. 343, No. 3, pgs. 299-302, (2001).
	AQ	KAZUTA, Y., et al., "Synthesis of (1S,2R)-1-Phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC) Derivatives Modified at the Carbamoyl Moiety As a New Class of NMDA Receptor Antagonists," <u>Bioorganic & Medicinal Chemistry</u> 10, pgs. 1777-1791, (2002).
	AR	LABAT, L., et al., "Separation of New Antidepressants and Their Metabolites by Micellar Electrokinetic Capillary Chromatography," <u>Journal of Chromatography B</u> , 773, pgs. 17-23, (2002).
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.		

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE